Questionnaire Survey on the Use of Depot Formulation of Leuprorelin Acetate Injection in Patients with Prostate Cancer (QLIPP)

Not Applicable

• Conditions: prostate cancer

• Registration Number: JPRN-UMIN000032045
• Lead Sponsor: Matsuyama Red Cross Hospital

Brief Summary

Fifty-seven percent of patients and 65% of caregivers showed a strong preference for the 6M formulation compared with the 3M formulation. There was no difference in the percentage of strong preference between the two groups, Among caregivers, there was a strong preference for the 6M drug in those who had to accompany their patients to the hospital (p<0.001). T

Detailed Description

Not available

Study Timeline

• Study Start: 2018-04-01
• Study Completion: 2018-08-07
• Results First Posted: 2020-08-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 127

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who have never prescribed luteinizing hormone-releasing hormone (LH-RH) agonist/LH-RH antagonist luteinizing hormone-releasing hormone (LH-RH) agonist/LH-RH antagonist 2.Caregivers of patients who cannot agree to participate in the study 3.Investigators, near relatives of investigators, investigator assistant, or near relatives of investigator assistant. 4.Who were judged clinically that responses to the questionnaire are improper or unsuitable by the principal investigator or collaborating physicians. 5.Who reject the participation of the study 6.Who wish to withdraw after the consent 7.When a false entry is identified

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To consider preferences of prostate cancer patients prescribed six-month depot formulation of Leuprorelin acetate injection and their caregivers, amongst 4 week depot (one-month depot formulation), 12 week depot formulation (three-month depot formulation), and six-month depot formulation, focusing on the following groups. - Patients who have difficulty visiting hospitals - Patients with high caregiver burden - Patients who change planned hospital visits frequently - Patients with multiple comorbidities at start of treatment

Secondary Outcome Measures

Name	Time	Method
To add consideration on the relationship between patient preference of six-month depot formulations and the following factors: reduction of the frequency of painful injections, reduction of annual medical expenses for prostate cancer treatment, reduction of the frequency of hospital visits, reduction of the burden of the caregiver, reduction of the frequency of consultations with the doctor, reduction of the time of stay at the hospital, improvement of the quality of life. To consider burdens of caregivers and preference of six-month depot formulations.